Masahiko Nakao

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Hironobu Hashimoto, Masakazu Abé, Osamu Tokuyama et al. · The Lancet Oncology · 2019 · 218 citations

Drug Safety, Chemotherapy-induced Nausea, Pharmacology +7

Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study

K. Suzuki, Takeharu Yamanaka, Hiroki Hashimoto et al. · Annals of Oncology · 2016 · 97 citations · Full text

Oncology, Metronomic Therapy, Pharmacology +6

A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy

Takako Yanai, Satoru Iwasa, Hironobu Hashimoto et al. · International Journal of Clinical Oncology · 2017 · 71 citations

Oncology, Pharmacology, Emetogenic Cisplatin-based Chemotherapy +5

Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study

Daiki Tsuji, Mari Yokoi, Kenichi Suzuki et al. · The Pharmacogenomics Journal · 2016 · 25 citations

Antiemetic Efficacy, Cisplatin-based Chemotherapy, Medicine +10

Potentially harmful excipients in neonatal medications: a multicenter nationwide observational study in Japan

Jumpei Saito, Naomi Nadatani, Makoto Setoguchi et al. · Journal of Pharmaceutical Health Care and Sciences · 2021 · 23 citations · Full text